ANTI-GP73 MONOCLONAL ANTIBODIES AND METHODS OF OBTAINING THE SAME
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
0 Citations
103 Claims
-
1-24. -24. (canceled)
-
25. An isolated antibody or antibody fragment thereof which binds to Golgi Protein 73 (“
- GP73”
), wherein the antibody comprises a domain or region selected from the group consisting of;
(a) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
1, (b) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (c) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
9, (d) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (e) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
17, (f) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (g) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
25, (h) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;
33, (j) a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37;
(m) variable heavy domain comprising the amino acid sequence of SEQ ID NO;
1 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
5, (n) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
9 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
13, (o) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
17 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
21, (p) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
25 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
29, (q) a variable heavy domain comprising the amino acid sequence of SEQ ID NO;
33 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;
37, (s) a variable heavy chain comprising a complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, (t) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (u) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, (v) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (w) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, (x) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (y) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, (z) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, (aa) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, (bb) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40, (cc) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
42, a CDR2 comprising the amino acid sequence of SEQ ID NO;
43, and CDR3 comprising the amino acid sequence of SEQ ID NO;
44;
(dd) a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
46, a CDR2 comprising the amino acid sequence of SEQ ID NO;
47, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
48;
(ee) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8, (ff) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
10, a CDR2 comprising the amino acid sequence of SEQ ID NO;
11, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
12, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
14, a CDR2 comprising the amino acid sequence of SEQ ID NO;
15, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16, (gg) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
18, a CDR2 comprising the amino acid sequence of SEQ ID NO;
19, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
20, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
22, a CDR2 comprising the amino acid sequence of SEQ ID NO;
23, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
24, (hh) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
26, a CDR2 comprising the amino acid sequence of SEQ ID NO;
27, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
28, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
30, a CDR2 comprising the amino acid sequence of SEQ ID NO;
31, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
32, and (ii) a variable heavy chain comprising a CDR 1 comprising the amino acid sequence of SEQ ID NO;
34, a CDR2 comprising the amino acid sequence of SEQ ID NO;
35, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
36, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
38, a CDR2 comprising the amino acid sequence of SEQ ID NO;
39, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
40. - View Dependent Claims (26, 27, 28, 29, 39, 48, 56, 61, 70, 71, 72, 73, 94, 95, 96, 97, 103)
- GP73”
-
30-38. -38. (canceled)
-
40-47. -47. (canceled)
-
49-55. -55. (canceled)
-
57-60. -60. (canceled)
-
62-69. -69. (canceled)
-
74-93. -93. (canceled)
-
98. (canceled)
-
99. A kit for assaying a test sample for fucosylated GP73, which kit comprises at least one capture binding protein, wherein the capture binding protein binds to GP73 or a fragment of GP73, at least one detection binding protein, wherein the detection binding protein binds to GP73 that is not bound by the capture binding protein, and instructions for assaying the test sample for GP73, wherein the at least one capture binding protein comprises a protein, antibody or antibody fragment whose binding to GP73 is insensitive to the presence or absence of a fucose sugar moiety on GP73 and the at least one detection binding protein comprises a protein, antibody or antibody fragment whose binding to GP73 is sensitive to fucosylation of GP73.
-
100. A kit for assaying a test sample for fucosylated GP73, which kit comprises at least one capture binding protein, wherein the capture binding protein binds to GP73 or a fragment of GP73, at least one detection binding protein, wherein the detection binding protein binds to GP73 that is not bound by the capture binding protein, and instructions for assaying the test sample for GP73, wherein the at least one capture binding protein comprises a protein, antibody or antibody fragment whose binding to GP73 is sensitive to fucosylation of GP73 and the at least one detection binding protein comprises a protein, antibody or antibody fragment whose binding to GP73 is insensitive to fucosylation of GP73.
-
101. (canceled)
-
102. (canceled)
Specification